PLUR - שווי פעילות pluri-biotech.com
Pluri Inc. (PLUR) is attracting leading cell biologists to create innovative placental therapy systems, leveraging its patent strategy and RSU programs. The company is advancing biopharmaceuticals and synthetic meat through strategic alliances with global industry leaders. This price chart at the 47.68 level complements data on sterile zone operations and production capacities, which are fully prepared to execute metabolic therapy plans.
Pluri (PLUR) - פילוחי מדדים ודוחות פיננסיים
The long-term reliability of the issuer is determined by the business's ability to capitalize on its technological advantages. The EV of Pluri Inc. reflects the total cost of acquiring the business, summing market capitalization and net debt. This chart allows for an assessment of the asset's real price, stripped of the influence of liquid funds. The dynamics of this metric are critical for Pluri Inc. during its expansion in the biomass market. The increase in value confirms the commercial potential within the artificial meat sector.